scholarly journals Investigation of association between LINC00673 rs11655237 C>T and Wilms tumor susceptibility

2019 ◽  
Vol 33 (7) ◽  
Author(s):  
Xiaofeng Gao ◽  
Wei Jia ◽  
Jinhong Zhu ◽  
Wen Fu ◽  
Shibo Zhu ◽  
...  
Cancer ◽  
2002 ◽  
Vol 96 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Jonathan L. Hecht ◽  
Benjamin H. Lee ◽  
Jack L. Pinkus ◽  
Geraldine S. Pinkus

2020 ◽  
Vol 22 (11) ◽  
Author(s):  
Ao Lin ◽  
Mingming Zhou ◽  
Rui‐Xi Hua ◽  
Jiao Zhang ◽  
Haixia Zhou ◽  
...  

2019 ◽  
Vol 39 (1) ◽  
Author(s):  
Peng Liu ◽  
Zhenjian Zhuo ◽  
Wenya Li ◽  
Jiwen Cheng ◽  
Haixia Zhou ◽  
...  

Abstract Wilms tumor is the most common renal malignancy that occurs in children. TP53 gene is considered as a tumor-suppressing gene through controlling cell growth. TP53 gene rs1042522 C>G (Arg72Pro) polymorphism is widely investigated in various types of cancers. However, it is not established if TP53 rs1042522 C>G polymorphism is a candidate variant for Wilms tumor risk. The aim of the study was to determine whether TP53 rs1042522 C>G polymorphism is responsible for the risk of Wilms tumor in Chinese children. All subjects (355 cases and 1070 controls) from four centers of China were genotyped for rs1042522 C>G polymorphism. The effect of rs1042522 C>G polymorphism on Wilms tumor prevalence was analyzed using logistic regression models. We failed to detect a significant relationship between rs1042522 C>G polymorphism and Wilms tumor risk. Further stratification analysis also could not detect a significant relationship. We conclude that TP53 rs1042522 C>G polymorphism might not have enough impact on the risk of Wilms tumor. More validation study with larger sample size will be required to better define the role of TP53 rs1042522 C>G polymorphism in Wilms tumor risk.


2012 ◽  
Vol 44 (3) ◽  
pp. 277-284 ◽  
Author(s):  
Dewi Astuti ◽  
Mark R Morris ◽  
Wendy N Cooper ◽  
Raymond H J Staals ◽  
Naomi C Wake ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Tongyi Lu ◽  
Li Li ◽  
Jinhong Zhu ◽  
Jiabin Liu ◽  
Ao Lin ◽  
...  

Wilms tumor is the most common type of renal malignancy in children. Previous studies have demonstrated that single nucleotide polymorphisms (SNPs) in the AURKA gene could predispose to several human malignancies. We recruited 145 cases and 531 cancer-free controls to investigate whether AURKA gene variants modify Wilms tumor susceptibility. Three AURKA SNPs (rs1047972 C>T, rs2273535 T>A, and rs8173 G>C) were genotyped by the Taqman methodology. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of association between AURKA SNPs and Wilms tumor risk. We found that only the rs8173 G>C polymorphism was significantly associated with Wilms tumor risk (GC vs. GG: adjusted OR (AOR) = 0.50, 95% CI = 0.35–0.73, P=0.0002; GC/CC vs. GG: AOR = 0.60, 95% CI = 0.42–0.88, P=0.008). Stratification analysis revealed that rs8173 GC/CC genotypes were associated with Wilms tumor risk among children aged >18 months (AOR = 0.56, 95% CI = 0.34–0.93, P=0.024), male children (AOR = 0.54, 95% CI = 0.33–0.90, P=0.017), and children with clinical stage III + IV diseases (AOR = 0.56, 95% CI = 0.35–0.90, P=0.017). Haplotype analysis indicated that the CAG haplotype was significantly associated with increased Wilms tumor risk. In conclusion, our findings indicated that the AURKA rs8173 G>C polymorphism was associated with decreased Wilms tumor risk in Chinese children.


Gene ◽  
2020 ◽  
Vol 754 ◽  
pp. 144839
Author(s):  
Li Ma ◽  
Rui-Xi Hua ◽  
Huiran Lin ◽  
Jinhong Zhu ◽  
Wen Fu ◽  
...  

Gene ◽  
2021 ◽  
Vol 783 ◽  
pp. 145571
Author(s):  
Ao Lin ◽  
Rui-Xi Hua ◽  
Mingming Zhou ◽  
Wen Fu ◽  
Jiao Zhang ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

The mechanism of action underlying trastuzumab (Herceptin) function is ascribed to binding of the Fab region of trastuzumab to the extracellular domain of the human epidermal growth factor receptor (HER2) (1). The transcriptional responses that follow signals transduced through trastuzumab binding to HER2 are less well understood. We mined published microarray and multiplexed gene expression data (2, 3) to understand in an unbiased fashion genes most differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab. We observed significantly increased and differential expression of the Wilms’ tumor susceptibility gene, WT1 in the tumors of breast cancer patients treated with trastuzumab.


Sign in / Sign up

Export Citation Format

Share Document